Lava Therapeutics
Lava Therapeutics was a clinical-stage biotech that developed bispecific and trispecific T cell engager immunotherapies for cancer and autoimmune diseases. The company was acquired by XOMA Royalty Corporation in November 2025 and delisted from Nasdaq.
- Company typePublic
- Founded2016
- HeadquartersUtrecht, Netherlands
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Lava Therapeutics does
Lava Therapeutics N.V. was a clinical-stage biotechnology company developing T cell engagers (TCEs), a class of bispecific immunotherapies designed to bridge a patient's T cells to tumor cells and trigger targeted cancer cell destruction. Incorporated in the Netherlands and headquartered in Utrecht, the company was founded in 2016 and went public in 2021 via a SPAC merger, trading on Nasdaq under the ticker LVTX. The platform progressed from early 1+1 bispecific formats toward more complex 2+1 and trispecific (1+1+1) architectures intended to improve tumor selectivity, address antigen heterogeneity, and modulate T cell activation.
The pipeline was oriented toward hematologic malignancies — including B-cell ALL and lymphoma — and the company had signaled intent to extend the platform into autoimmune disease indications. Because LAVA was pre-commercial, its prospective revenue model was based on future licensing and royalties rather than product sales. Prior to any commercial launch, a clinical trial failure prompted operational downsizing.
In August 2025, XOMA Royalty Corporation announced a share purchase agreement to acquire LAVA; in October 2025 the cash component was reduced and the tender deadline extended. The acquisition closed on November 21, 2025, with shareholders receiving cash and contingent value rights, after which LAVA became a wholly-owned subsidiary of XOMA Royalty and was delisted from Nasdaq.
Lava Therapeutics firmographics
Firmographics- Name
- Lava Therapeutics
- Legal name
- LAVA Therapeutics N.V.
- Website
- https://lavatherapeutics.com
- Company type
- Public
- Founded year
- 2016
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Lava Therapeutics was a clinical-stage biotech that developed bispecific and trispecific T cell engager immunotherapies for cancer and autoimmune diseases. The company was acquired by XOMA Royalty Corporation in November 2025 and delisted from Nasdaq.
- Ownership category
- akta.pro rank
Lava Therapeutics industry classification
Industry- Product category
- Bispecific Antibody Therapeutics / Cancer Immunotherapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Bispecific & Multispecific Antibodies (HLAAAAAF)
Keywords
Where Lava Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Utrecht
- HQ country
- Netherlands
- HQ region
- Europe
Markets served
Lava Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Biopharmaceutical Development: As a clinical-stage biotech, LAVA Therapeutics was developing T cell engager therapies for cancer treatment. The company had not yet commercialized products and was acquired by XOMA Royalty before achieving product revenue.
Marketing channels1 record
Lava Therapeutics product offering
Product offeringCore offering
Lava Therapeutics developed bispecific T cell engager (TCE) immunotherapies that bridge T cells to tumor cells to trigger targeted cancer cell destruction. The platform progressed from 1+1 bispecific formats to next-generation 2+1 and trispecific (1+1+1) designs intended to improve tumor selectivity and address challenges such as antigen heterogeneity, cytokine release syndrome, and short half-life. Primary indications targeted hematologic malignancies including B-cell ALL and lymphoma, with potential applications in solid tumors and autoimmune diseases.
Product overview
Lava Therapeutics is a clinical-stage biotech company specializing in innovative immunotherapies for cancer and autoimmune diseases. The company was developing T cell engager (TCE) bispecific immunotherapies, leveraging next-generation formats to bridge T cells to tumor cells for targeted cancer cell destruction. Following XOMA Royalty's acquisition completed in November 2025, the company has been delisted from Nasdaq.
Differentiator
Problem solved
Functional benefit
Products and services
- Bispecific gamma-delta T cell engager (TCE) pipeline Proprietary clinical-stage pipeline of bispecific and trispecific T cell engagers designed to redirect T cells to tumor cells for targeted cancer cell destruction, developed for oncology indications such as B-cell acute lymphoblastic leukemia and lymphoma. Targeted at biopharma partners and ultimately oncology patients via future commercialization partners.
Companies that use Lava Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
Lava Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Lava Therapeutics partnerships and signals
Strategic signalScale indicators3 records
Recent moves5 records
Expansion highlights4 records
Lava Therapeutics competitors and assessment
Company assessmentMarket position
Competitive moat2 records
Key risks6 records
Key highlights5 records
Customer concentration
Lava Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lava Therapeutics leadership team
Management profileNumber of profiles
Profiles6 records
Lava Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lava Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lava Therapeutics
What does Lava Therapeutics do?
Lava Therapeutics developed bispecific T cell engager (TCE) immunotherapies that bridge T cells to tumor cells to trigger targeted cancer cell destruction. The platform progressed from 1+1 bispecific formats to next-generation 2+1 and trispecific (1+1+1) designs intended to improve tumor selectivity and address challenges such as antigen heterogeneity, cytokine release syndrome, and short half-life. Primary indications targeted hematologic malignancies including B-cell ALL and lymphoma, with potential applications in solid tumors and autoimmune diseases.
Is Lava Therapeutics a public or private company?
Lava Therapeutics is a public company. It is classified as corporate owned and is currently acquired.
When was Lava Therapeutics founded?
Lava Therapeutics was founded in 2016. It employs 11 to 50 people.
Where is Lava Therapeutics based?
Lava Therapeutics is headquartered in Utrecht, Netherlands, in the Europe region.
How does Lava Therapeutics make money?
One revenue line is on record: biopharmaceutical Development.
Does Lava Therapeutics have an API?
No public API is recorded for Lava Therapeutics.
What industry is Lava Therapeutics in?
Lava Therapeutics's product category is Bispecific Antibody Therapeutics / Cancer Immunotherapy. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 325414 and its SIC code is 2834.